# Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
**DATES:**
Submit written comments (including recommendations) on the collection of information by April 13, 2026.
**ADDRESSES:**
To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0309.
**FOR FURTHER INFORMATION CONTACT:**
Amber Barrett, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, *[email protected]* .
**SUPPLEMENTARY INFORMATION:**
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
**Mammography Quality Standards Act Requirements—21 CFR Part 900**
**OMB Control Number 0910-0309—Extension**
The Mammography Quality Standards Act (Pub. L. 102-539) requires the establishment of a Federal certification and inspection program for mammography facilities; standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. Implementing regulations are found in part 900 (21 CFR part 900). The regulations are intended to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance, and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.
FDA meets with its National Mammography Quality Assurance Advisory Committee (NMQAAC) for the purposes of advising FDA's mammography program on advances in mammography technology and procedures and on appropriate quality standards for mammography facilities. NMQAAC is made up of representatives of the mammography community, consumer and industry groups, and government. The meetings are open to the public and time is allotted for public statements on issues of concern in the mammography field. The chairperson may also call upon attendees to contribute to the committee discussions.
FDA also regularly meets or holds teleconferences with its approved accreditation bodies and State certification agencies to discuss issues of mutual concern. We also engage with the Conference of State Radiation Program Directors (CRCPD), a professional organization of State agencies concerned with radiation protection. The CRCPD has established a standing Mammography Committee, which meets with FDA mammography staff at least once a year.
Finally, in recent years, FDA mammography staff have met several times with representatives of manufacturers working on the new applications of digital technology in mammography to resolve problems preventing the making of that technology generally available. FDA mammography staff have also worked with representatives of the manufacturers to develop quality assurance manuals for full field digital mammography units.
In the *Federal Register* of December 9, 2025 (90 FR 57070), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.
FDA estimates the burden of this collection of information as follows:
| Activity/21 CFR section/FDA form No. | Number of | Number of | Total | Average burden per response | Total hours |
| --- | --- | --- | --- | --- | --- |
| | | | | | |
| | | | | | |
| Notification of intent to become an AB—900.3(b)(1) | 0.33 | 1 | 0.33 | 1 | 1 |
| Application for approval as an AB; full
—900.3(b)(3) | 0.33 | 1 | 0.33 | 320 | 106 |
| Application for approval as an AB; limited
—900.3(b)(3) | 5 | 1 | 5 | 30 | 150 |
| AB renewal of approval—900.3(c) | 1 | 1 | 1 | 15 | 15 |
| AB application deficiencies—900.3(d)(2) | 0.1 | 1 | 0.1 | 30 | 3 |
| AB resubmission of denied applications—900.3(d)(5) | 0.1 | 1 | 0.1 | 30 | 3 |
| Letter of intent to relinquish accreditation authority—900.3(e) | 0.1 | 1 | 0.1 | 1 | 1 |
| Summary report describing all facility assessments—900.4(f) | 338 | 1 | 338 | 7 | 2,366 |
| AB reporting to FDA; facility
—900.4(h) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| AB reporting to FDA; AB
—900.4(h) | 5 | 1 | 5 | 10 | 50 |
| AB financial records—900.4(i)(2) | 1 | 1 | 1 | 16 | 16 |
| Former AB new application—900.6(c)(1) | 0.1 | 1 | 0.1 | 60 | 6 |
| Total Subpart A | | | | | 11,648 |
| | | | | | |
| Reconsideration of accreditation following appeal—900.15(d)(3)(ii) | 1 | 1 | 1 | 2 | 2 |
| Application for alternative standard—900.18(c) | 2 | 1 | 2 | 2 | 4 |
| Alternative standard amendment—900.18(e) | 10 | 1 | 10 | 1 | 10 |
| Total Subpart B | | | | | 16 |
| | | | | | |
| Certification agency application—900.21(b) | 0.33 | 1 | 0.33 | 320 | 106 |
| Certification agency application deficiencies—900.21(c)(2) | 0.1 | 1 | 0.1 | 30 | 3 |
| Certification electronic data transmission—900.22(h) | 5 | 200 | 1000 | 0.083 (5 minutes) | 83 |
| Changes to standards—900.22(i) | 2 | 1 | 2 | 30 | 60 |
| Certification agency minor deficiencies—900.24(b) | 1 | 1 | 1 | 30 | 30 |
| Appeal of adverse action taken by FDA—900.25(a) | 0.2 | 1 | 0.2 | 16 | 3 |
| Total Subpart C | | | | | 285 |
| Inspection fee exemption—FDA Form 3422 | 355 | 1 | 355 | 0.25 (15 minutes) | 89 |
| Total | | | | | 12,038 |
| Activity/21 CFR section | Number of | Number of | Total | Average burden per recordkeeping | Total hours |
| --- | --- | --- | --- | --- | --- |
| | | | | | |
| | | | | | |
| AB transfer of facility records—900.3(f)(1) | 0.1 | 1 | 0.1 | 1 | 1 |
| Consumer complaints system; AB—900.4(g) | 5 | 1 | 5 | 1 | 5 |
| Total Subpart A | | | | | 6 |
| | | | | | |
| Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2) | 89 | 1 | 89 | 8 | 712 |
| Documentation of interpreting physician personnel requirements—900.12(a)(4) | 8,931 | 4 | 35,724 | 1 | 35,724 |
| Permanent medical record—900.12(c)(4) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| Procedures for cleaning equipment—900.12(e)(13) | 8,931 | 52 | 464,412 | 0.083 (5 minutes) | 38,546 |
| Audit program—900.12(f) | 8,931 | 1 | 8,931 | 16 | 142,896 |
| Consumer complaints system; facility—900.12(h)(2) | 8,931 | 2 | 17,862 | 1 | 17,862 |
| Total Subpart B | | | | | 244,671 |
| | | | | | |
| Certification agency conflict of interest—900.22(a) | 4 | 1 | 4 | 1 | 4 |
| Processes for suspension and revocation of certificates—900.22(d) | 4 | 1 | 4 | 1 | 4 |
| Processes for appeals—900.22(e) | 4 | 1 | 4 | 1 | 4 |
| Processes for additional mammography review—900.22(f) | 4 | 1 | 4 | 1 | 4 |
| Processes for patient notifications—900.22(g) | 3 | 1 | 3 | 1 | 3 |
| Evaluation of certification agency—900.23 | 4 | 1 | 4 | 20 | 80 |
| Appeals—900.25(b) | 4 | 1 | 4 | 1 | 4 |
| Total Subpart C | | | | | 103 |
| Total | | | | | 244,774 |
| Activity/21 CFR section | Number of | Number of | Total annual | Average burden per disclosure | Total hours |
| --- | --- | --- | --- | --- | --- |
| | | | | | |
| | | | | | |
| Notification of facilities that AB relinquishes its accreditation—900.3(f)(2) | 0.1 | 1 | 0.1 | 200 | 20 |
| Clinical images; facility
—900.4(c), 900.11(b)(1), and 900.11(b)(2) | 2,955 | 1 | 2,955 | 1.44 | 4,255 |
| Clinical images; AB
—900.4(c) | 5 | 1 | 5 | 416 | 2,080 |
| Phantom images; facility
—900.4(d), 900.11(b)(1), and 900.11(b)(2) | 2,955 | 1 | 2,955 | 0.72 (43 minutes) | 2,128 |
| Phantom images; AB
—900.4(d) | 5 | 1 | 5 | 208 | 1,040 |
| Annual equipment evaluation and survey; facility
—900.4(e), 900.11(b)(1), and 900.11(b)(2) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| Annual equipment evaluation and survey; AB
—900.4(e) | 5 | 1 | 5 | 1,730 | 8,650 |
| Total Subpart A | | | | | 27,104 |
| | | | | | |
| Provisional mammography facility certificate extension application—900.11(b)(3) | 2 | 1 | 2 | 0.5 (30 minutes) | 1 |
| Mammography facility certificate reinstatement application—900.11(c) | 288 | 1 | 288 | 5 | 1,440 |
| Provision of personnel records to IPs—900.12(a)(4) | 615 | 1 | 615 | 0.08 (5 minutes) | 49 |
| Transfer of personnel records by closing facilities—900.12(a)(4) | 190 | 1 | 190 | 5 | 950 |
| New assessment categories and breast density reporting in mammography report (one-time burden)—900.12(c)(1)(iv) to (vi) | 8,931 | 1 | 8,931 | 23 | 205,413 |
| Lay summary of examination—900.12(c)(2) | 8,931 | 5,085 | 45,414,135 | 0.083 (5 minutes) | 3,769,373 |
| Breast density reporting in lay summary (one-time burden)—900.12(c)(2) | 8,931 | 1 | 8,931 | 11 | 98,241 |
| Lay summary of examination; patient refusal
—900.12(c)(2) | 89 | 1 | 89 | 0.5 (30 minutes) | 45 |
| Transfer/provision of copies of mammograms and records upon patient's request—900.12(c)(4)(ii) and (iii) | 8,931 | 520 | 4,644,120 | 0.08 (5 minutes) | 371,530 |
| Facility closure; notification and records access—900.12(c)(4)(v) | 190 | 1 | 190 | 32 | 6,080 |
| Report of unresolved serious complaints—900.12(h)(4) | 20 | 1 | 20 | 1 | 20 |
| Information regarding compromised quality; facility
—900.12(j)(1) | 20 | 1 | 20 | 200 | 4,000 |
| Information regarding compromised quality; AB
—900.12(j)(1) | 20 | 1 | 20 | 320 | 6,400 |
| Patient notification of serious risk—900.12(j)(2) | 7 | 1 | 7 | 100 | 700 |
| Reconsideration of accreditation—900.15(c) | 5 | 1 | 5 | 2 | 10 |
| Total Subpart B | | | | | 4,464,252 |
| | | | | | |
| Notification of requirement to correct major deficiencies—900.24(a) | 0.4 | 1 | 0.4 | 200 | 80 |
| Notification of loss of approval; major deficiencies—900.24(a)(2) | 0.15 | 1 | 0.15 | 100 | 15 |
| Notification of probationary status—900.24(b)(1) | 0.3 | 1 | 0.3 | 200 | 60 |
| Notification of loss of approval; minor deficiencies—900.24(b)(3) | 0.15 | 1 | 0.15 | 100 | 15 |
| Total Subpart C | | | | | 170 |
| Total | | | | | 4,491,526 |
Our estimated burden for the information collection reflects an overall decrease of 4,225,729 hours and a corresponding decrease of 321,202 responses. We attribute this adjustment due to the number of certified mammography facilities. The estimated number of respondents in the tables are based on the number (8,931) of certified mammography facilities as of October 1, 2024. Title 21 CFR part 900 Mammography, as amended, includes various reporting, recordkeeping, and third-party disclosure activities. In addition, there was a decrease in state certifiers from 5 to 4—Illinois, Iowa, South Carolina, and Texas.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.